Furthermore, combining BRAF inhibitors with MEK inhibitors or other immunomodulatory agents could enhance the effectiveness of immunological therapies by preventing MAPK pathway feedback activation and promoting T-cell infiltration into the tumor microenvironment. Here, MAP2K7 is linked to neoplasm.